Literature DB >> 26875663

Astrocyte membrane properties are altered in a rat model of developmental cortical malformation but single-cell astrocytic glutamate uptake is robust.

Elizabeth Hanson1, Niels Christian Danbolt2, Chris G Dulla1.   

Abstract

Developmental cortical malformations (DCMs) are linked with severe epilepsy and are caused by both genetic and environmental insults. DCMs include several neurological diseases, such as focal cortical dysplasia, polymicrogyria, schizencephaly, and others. Human studies have implicated astrocyte reactivity and dysfunction in the pathophysiology of DCMs, but their specific role is unknown. As astrocytes powerfully regulate glutamate neurotransmission, and glutamate levels are known to be increased in human epileptic foci, understanding the role of astrocytes in the pathological sequelae of DCMs is extremely important. Additionally, recent studies examining astrocyte glutamate uptake in DCMs have reported conflicting results, adding confusion to the field. In this study we utilized the freeze lesion (FL) model of DCM, which is known to induce reactive astrocytosis and cause significant changes in astrocyte morphology, proliferation, and distribution. Using whole-cell patch clamp recording from astrocytes, we recorded both UV-uncaging and synaptically evoked glutamate transporter currents (TCs), widely accepted assays of functional glutamate transport by astrocytes. With this approach, we set out to test the hypothesis that astrocyte membrane properties and glutamate transport were disrupted in this model of DCM. Though we found that the developmental maturation of astrocyte membrane resistance was disrupted by FL, glutamate uptake by individual astrocytes was robust throughout FL development. Interestingly, using an immunolabeling approach, we observed spatial and developmental differences in excitatory amino acid transporter (EAAT) expression in FL cortex. Spatially specific differences in EAAT2 (GLT-1) and EAAT1 (GLAST) expression suggest that the relative contribution of each EAAT to astrocytic glutamate uptake may be altered in FL cortex. Lastly, we carefully analyzed the amplitudes and onset times of both synaptically- and UV uncaging-evoked TCs. We found that in the FL cortex, synaptically-evoked, but not UV uncaging-evoked TCs, were larger in amplitude. Additionally, we found that the amount of electrical stimulation required to evoke a synaptic TC was significantly reduced in the FL cortex. Both of these findings are consistent with increased excitatory input to the FL cortex, but not with changes in how individual astrocytes remove glutamate. Taken together, our results demonstrate that the maturation of astrocyte membrane resistance, local distribution of glutamate transporters, and glutamatergic input to the cortex are altered in the FL model, but that single-cell astrocytic glutamate uptake is robust.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortical malformation; EAAT1; EAAT2; Epilepsy; GLAST; GLT-1; Glial development; Glutamate; Glutamate transport; Membrane resistance

Mesh:

Substances:

Year:  2016        PMID: 26875663      PMCID: PMC4794447          DOI: 10.1016/j.nbd.2016.02.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  43 in total

1.  Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.

Authors:  Susan L Campbell; John J Hablitz
Journal:  Neurobiol Dis       Date:  2008-07-15       Impact factor: 5.996

Review 2.  Malformations of cortical development: clinical features and genetic causes.

Authors:  Renzo Guerrini; William B Dobyns
Journal:  Lancet Neurol       Date:  2014-06-02       Impact factor: 44.182

3.  Extracellular metabolites in the cortex and hippocampus of epileptic patients.

Authors:  Idil Cavus; Willard S Kasoff; Michael P Cassaday; Ralph Jacob; Ralitza Gueorguieva; Robert S Sherwin; John H Krystal; Dennis D Spencer; Walid M Abi-Saab
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

4.  Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo.

Authors:  Axel Nimmerjahn; Frank Kirchhoff; Jason N D Kerr; Fritjof Helmchen
Journal:  Nat Methods       Date:  2004-09-29       Impact factor: 28.547

5.  Hyperexcitability in a model of cortical maldevelopment.

Authors:  K M Jacobs; M J Gutnick; D A Prince
Journal:  Cereb Cortex       Date:  1996 May-Jun       Impact factor: 5.357

6.  Differential developmental expression of the two rat brain glutamate transporter proteins GLAST and GLT.

Authors:  K Ullensvang; K P Lehre; J Storm-Mathisen; N C Danbolt
Journal:  Eur J Neurosci       Date:  1997-08       Impact factor: 3.386

7.  Increased coupling and altered glutamate transport currents in astrocytes following kainic-acid-induced status epilepticus.

Authors:  D K Takahashi; J R Vargas; K S Wilcox
Journal:  Neurobiol Dis       Date:  2010-08-05       Impact factor: 5.996

Review 8.  Mechanisms underlying epileptogenesis in cortical malformations.

Authors:  K M Jacobs; V N Kharazia; D A Prince
Journal:  Epilepsy Res       Date:  1999-09       Impact factor: 3.045

9.  Glutamate biosensor imaging reveals dysregulation of glutamatergic pathways in a model of developmental cortical malformation.

Authors:  C G Dulla; H Tani; J Brill; R J Reimer; J R Huguenard
Journal:  Neurobiol Dis       Date:  2012-09-11       Impact factor: 5.996

10.  Laser-scanning astrocyte mapping reveals increased glutamate-responsive domain size and disrupted maturation of glutamate uptake following neonatal cortical freeze-lesion.

Authors:  Moritz Armbruster; David Hampton; Yongjie Yang; Chris G Dulla
Journal:  Front Cell Neurosci       Date:  2014-09-09       Impact factor: 5.505

View more
  1 in total

1.  α2δ-1 Signaling Drives Cell Death, Synaptogenesis, Circuit Reorganization, and Gabapentin-Mediated Neuroprotection in a Model of Insult-Induced Cortical Malformation.

Authors:  Lauren A Lau; Farzad Noubary; Dongqing Wang; Chris G Dulla
Journal:  eNeuro       Date:  2017-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.